What can we help you find?
Concluding the discussion, the panel considers future directions for subcutaneous dosing.
Experts move on to discuss the various levels of financial benefit with subcutaneous dosing.
Practical considerations regarding the dosing of subcutaneous formulations
Key opinion leaders break down the pharmacokinetic properties of subcutaneous formulations.
Experts discuss who and what is involved in adding subcutaneous formulations to the formulary.
A panel of experts reviews the benefits of subcutaneous dosing from the patient perspective.
Factors that inform the decision to stratify patients to subcutaneous formulations.
Potential clinical and financial causes for hesitation in the transition to subcutaneous dosing are addressed.
Experts provide perspective on how they prepare their staff for the transition to subcutaneous dosing.
The differences in subcutaneous formulation preparation and the corresponding impact on practice.
Experts consider the reasoning behind flat dosing of subcutaneous formulations, as well as its added benefit.
A discussion on the role of payers in the oral oncolytic dispensing process.